XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
   Esomeprazole
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04
Research Article
American Journal of Gastroenterology

Esomeprazole Channel
subscribe to Esomeprazole newsletter

Latest Research : Pharmacology : PPI : Esomeprazole

   DISCUSS   |   EMAIL   |   PRINT
Esomeprazole can reduce upper GI symptoms in patients using NSAIDS
May 13, 2005, 17:04, Reviewed by: Dr.

“People who use NSAIDs regularly are at a high risk for upper GI disturbances including dyspepsia, abdominal pain, and heartburn. Although reducing the NSAID dosage or discontinuing therapy might ease GI symptoms, these alterations often are not an option for many patients because of the chronic nature of their underlying condition. These two trials demonstrate that NEXIUM was effective in reducing upper GI symptoms of patients on chronic NSAID therapy.”

 
Results from two clinical trials, published in the American Journal of Gastroenterology, demonstrate that NEXIUM® (esomeprazole magnesium) can reduce upper gastrointestinal (GI) symptoms – such as moderate to severe pain, burning and discomfort in the upper abdomen– associated with continuous, daily use of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors.

In the trials, NEXIUM 20 mg and 40 mg significantly improved upper GI symptoms in patients taking NSAIDs, including selective COX-2 inhibitors, versus placebo.

“People who use NSAIDs regularly are at a high risk for upper GI disturbances including dyspepsia, abdominal pain, and heartburn. Although reducing the NSAID dosage or discontinuing therapy might ease GI symptoms, these alterations often are not an option for many patients because of the chronic nature of their underlying condition,” said James M. Scheiman, M.D., Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. “These two trials demonstrate that NEXIUM was effective in reducing upper GI symptoms of patients on chronic NSAID therapy.”

NEXIUM improved symptoms in as early as the second day of treatment and provided significantly faster symptom relief, compared with placebo. In one trial, 7 consecutive days of symptom relief occurred within an average of 11 and 10 days for patients treated with NEXIUM 20 mg and 40 mg, respectively, versus 17 days for placebo. In the other trial, 7 consecutive days of symptom relief occurred within an average of 10 and 11 days for patients treated with NEXIUM 20 mg and 40 mg, respectively, versus 21 days for placebo.

In addition, over the four week treatment period, the proportion of symptom-free days was significantly higher for patients treated with NEXIUM versus placebo in both trials (31 percent and 29 percent, vs. 21 percent, and 29 percent and 27 percent, vs. 14 percent in the two trials). More patients treated with NEXIUM (20 mg or 40 mg) also reported improvements on an overall treatment assessment after four weeks of treatment, versus placebo (70.6 percent and 56.8 percent for NEXIUM 20 mg, and 61.1 percent and 54.7 percent for NEXIUM 40 mg, compared with 47.7 percent and 40.9 percent for placebo in these trials).

About the Trials The clinical research trials were two identical, randomized, double-blind, placebo-controlled trials involving a total of 595 and 554 patients, respectively, who were continuous NSAID users and who did not have gastric ulcers, erosive esophagitis or H. pylori infection. Approximately one-third of the patients in both trials (30 percent, 38 percent) were taking only selective COX-2 inhibitors. In the trials, patients received NEXIUM 20 mg or 40 mg or placebo.

In both trials, the safety profile of NEXIUM 20 mg and 40 mg among continuous NSAID users was similar to placebo.
 

- American Journal of Gastroenterology
 

www.astrazeneca.com

 
Subscribe to Esomeprazole Newsletter
E-mail Address:

 

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. For full prescribing information for NEXIUM please visit www.purplepill.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information about AstraZeneca, please visit: www.astrazeneca-us.com


Related Esomeprazole News

Esomeprazole can reduce upper GI symptoms in patients using NSAIDS


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us